A 65-year-old man is evaluated in the general internal medicine clinic prior to an elective colonoscopy with planned polypectomy. He has a history of a mechanical mitral valve replacement and takes warfarin daily. His target international normalized ratio (INR) is 2.5 to 3.5. The patient is considered to be at high risk for thromboembolism, and bridging therapy is indicated.
Arrange the following steps for periprocedural anticoagulation management in the correct chronological sequence.
- 1Discontinue warfarin therapy 5 days prior to the procedure
- 2Initiate bridging therapy with subcutaneous low-molecular-weight heparin
- 3Hold the dose of low-molecular-weight heparin 24 hours prior to the procedure
- 4Resume warfarin therapy on the evening following the procedure
Answer
The correct chronological sequence is to first discontinue warfarin 5 days prior, then initiate bridging therapy with LMWH 3 days prior, then hold the LMWH dose 24 hours prior, and finally resume warfarin on the evening after the procedure.
The standard protocol for bridging high-risk patients on warfarin involves stopping warfarin on day -5 to allow INR normalization. Bridging with LMWH begins on day -3 as the INR falls subtherapeutic. The LMWH is held on day -1 (24 hours prior) to clear the anticoagulant effect before surgery. Finally, warfarin is resumed on day 0 (evening post-procedure) once hemostasis is secure.
Step-by-Step Solution
Key Concept
Periprocedural management of anticoagulation in high-risk patients requires stopping warfarin 5 days prior, bridging with LMWH when the INR falls, holding LMWH 24 hours before the procedure, and resuming warfarin post-procedure.